hotspot -WSS

hotspot

author：entertainment 2025-10-01 02:28:08 - browse：84

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Why are Kaiser Permanente staff considering a strike?

focus

WSS

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Reports of telehealth's death have been greatly exaggerated

Biotech stock slump in 2023: awaiting the turnaround

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Hearing on Medicare drug price negotiation gets unusually heated

FDA poised to publish guidelines for clinical trial diversity

knowledge

hotspot

focus

New air purifier tech could be key to improving indoor air quality

Liver decline slowed by off

The cancer drug shortage isn’t new — and neither are the solutions

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Virginia high school admissions case could be legal follow

Ukraine and a new approach to mental health in war

Medical records are filled with copy

Hearing on Medicare drug price negotiation gets unusually heated

Cancer drug shortages should be causing more outrage

EpiPen alternative approval delay highlights citizen petition issue

entertainment

Scrutiny of post

Listen: More tumult at BIO & coercive care for sickle cell patients

Senators: Long

As a primary care physician, here's how I hope to partner with AI

How Vertex's cystic fibrosis drug is changing patients' lives

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

focus

focus

knowledge

focus